Abstract. To assess the immunogenicity of more economical regimens of Haemophilus influenzae type b (Hib) conjugate vaccine, a randomized trial of fractional doses of polyribosylribitol phosphate-tetanus toxoid (PRP-T) Hib vaccine was undertaken in the Dominican Republic. Six hundred children were assigned to one of six regimens with PRP-T vaccine: full-dose, half-dose, and one-third-dose of Hib vaccine given separately or combined with diphtheria, tetanus, and pertussis (DTP) vaccine at ages 2, 4, and 6 months. Regimens that elicited antibody levels Ͼ 1.0 g/ mL in Ͼ70% of children and Յ 0.15 g/mL in Ͼ 90% of children were considered acceptable. At 1 month post Dose 3, all regimens met the criteria for acceptable response. Among those who received Hib as a separate injection, geometric mean concentrations of anti-PRP bodies (GMCs) at age 1 month post Dose 3 were 11.2, 11.9, and 16.3 in the full, half, and one-third dose groups, respectively. Among those who received Hib and DTP combined, the GMCs were 6.4, 5.2, and 5.7 in the full-, half-, and one-third-dose groups respectively.
INTRODUCTION
The widespread use of Haemophilus influenzae (Hib) type b conjugate vaccines in industrialized countries has led to near-elimination of Hib disease in young children. [1] [2] [3] The efficacy of the vaccine in developing countries is well established. [4] [5] [6] [7] Thus, Hib disease is now a major cause of vaccinepreventable morbidity and mortality in young children in developing countries. [8] [9] [10] Despite these achievements, few developing countries are using Hib vaccine in their routine immunization program. The major obstacle to the routine use of Hib conjugate vaccine in most non-industrialized countries is cost. Although the vaccine has been available since the early 1990s, the current market price of the vaccine is approximately US$2.50 per dose. By contrast, each of six basic antigens delivered through the Expanded Program on Immunizations (EPI) (diphtheria, tetanus, and pertussis, [DTP] , Bacille Calmette-Guérin [BCG]), measles, and oral polio vaccine [OPV] ) costs less than US$0.15 per dose. This makes Hib vaccine expensive for developing countries and even for many newly industrialized countries. More economical approaches to Hib vaccine use (i.e., the use of fractional dose or fewer dose regimens) may reduce the cost of the vaccination making it more affordable for countries with few resources.
Many regimens of Hib vaccination have been shown to protect against Hib disease. For example, in industrialized countries, several different schedules of routine Hib vaccination have been used, and all have been successful. 11, 12 The United States and Uruguay give the vaccine at ages 2, 4, 6, and 12-18 months; the United Kingdom at ages 2, 3, and 4 months; Chile at ages 2, 4, and 6 months; and Finland at ages 3, 5, and 12 months. Despite the differences in schedules, widespread vaccination in each of these countries has reduced Hib-invasive disease rates in children Ͻ 5 years old by Ն 90%. Immunogenicity studies also suggest that regimens of reduced dose or fewer doses may protect infants. 7, [13] [14] [15] [16] To assess the immunogenicity of fractional doses of Hib vaccine, we conducted a clinical trial of six alternative regimens selected by the Dominican Health Ministry as potentially practical for routine use in the Dominican Republic.
MATERIALS AND METHODS
Patients and eligibility. The protocol was reviewed by the National Ethics Committee in the Dominican Republic and the Human Subjects Committee of the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. Healthy infants with a birth weight of Ն 2,500 g who presented to the Centro Sanitario clinic (Santo Domingo, Dominican Republic) for their first dose of DTP vaccine were eligible to participate. We obtained written, informed consent from the parent or guardian who accompanied each infant. Exclusion criteria included any of the following: previous DTP or Hib vaccination, contraindication to receiving DTP or Hib vaccination, major chronic or congenital disease, known immunologic disorders, or residence outside the Distrito Nacional.
Study groups and randomization. At enrollment, each infant was assigned a study number. A list of these numbers had been randomized in blocks of 6, relegating each infant to 1 of 6 immunization regimens. Infants were recruited between June 29 and August 5, 1998 .
Vaccine formulations and administration of fractional doses. Oral polio, hepatitis B, and BCG vaccine were obtained from the EPI stock and administered according to the local schedule. We used ActHib, a Hib polysaccharide tetanus toxoid conjugate vaccine, in single 10 mcg dose vials and whole-cell DTP vaccine in 10-dose vials (both produced by Pasteur Mérieux Connaught, Lyon, France). For infants randomized to receive Hib and DTP vaccines separately, lyophilized PRP-T was reconstituted with sterile diluent provided by the manufacturer and injected within 4 hrs. For infants receiving a full dose of Hib vaccine, PRP-T vaccine was reconstituted with 0.6 mL of diluent; one 0.5 mL dose of the resulting vaccine was then withdrawn and injected intramuscularly. For infants receiving reduced-antigen doses, 2 (for half dose) or 3 (for one-third dose) times the amount of diluent was added, resulting in 2 or 3 0.5 mL doses respectively, of which 0.5 mL volume were withdrawn and injected per infant. For infants receiving PRP-T combined with DTP, the same procedure was used but liquid DTP was used as the diluent to reconstitute the Hib vaccine. The vaccine formulations were prepared on-site, and thus the nature of the individual vaccination regimens were not concealed from either the vaccinators or the parents.
The parents/guardians received telephone calls to remind them of follow-up appointments. Those who were not on time received reminder calls and visits.
Blood samples and analysis of the serology. Blood specimens were obtained by venipuncture from a sample of 30 infants prior to the first vaccination (at 2 months of age), from all infants prior to the second (at age 4 months) and third (at 6 months) vaccinations, and one month after the third vaccination. Serum was coded and kept at Ϫ70ЊC until it was shipped to the CDC in Atlanta, GA. We measured anti-IgG antibodies by means of a quantitative enzymelinked immunosorbent assay (ELISA). All specimens from the same infant were tested in parallel. Laboratory technicians were blinded to the participants' vaccine regimens.
Antibody concentrations specific for the Hib polybosylribitol phosphate (PRP) capsule were determined by a modification of the ELISA method described by Madore and others. 17 Briefly, a solution of 1 g/mL of Hib oligosaccharide conjugated to human albumin (HbOHA, provided by Dr. Moon H. Nahm, University of Rochester, NY) was used to coat Immulon 2 microtiter plates (Dynatech Laboratories, Inc., Chantilly, VA) at 37ЊC for 90 min, followed by 4ЊC storage until use. Serum samples were stored frozen at Ϫ70ЊC, and thawed prior to the assay. Serum samples were diluted 1:50 in 0.01 M PBS with 0.3% Tween 20, pH 7.0-7.4. Samples were allowed to react for 1 hr at room temperature. Unbound antibodies were washed five times in the same buffer. A 1:16,000 dilution of mouse anti-human IgG monoclonal antibody (clone HP6043) conjugated to horseradish peroxidase (Hybridoma Reagent Laboratories, Baltimore, MD) was used for the detection of bound human IgG antibodies by incubation at room temperature for 2 hr. Unbound conjugate was removed by washing, and the reaction was developed by the addition of tetramethylbenzidine (TMB) substrate (Kinkegard and Perry Laboratories, Gaithersburg, MD). Optical densities were measured in a Ceres 900 ELISA reader (Bio-Tek Instruments, Inc., Winooski, VE) at a wavelength of 450/620 nm. Antibody concentrations were calculated against a standard curve of the reference serum (lot 1983, 60.9 g/mL; provided by Dr. Carl Frasch, Center for Biological Evaluation and Review; Food and Drug Administration, Bethesda, MD) using a four-parameter logistic curve fitting technique. 18 The bacterial polysaccharide immune globulin 19 was used as the quality control preparation in each plate at a 1:20,000 dilution. 20 Interassay coefficient of variance was calculated to 15.2% using 50 independent runs of the quality control preparation. The minimum level of detection of the ELISA assay was 0.12 mcg/ mL at 1:50 serum dilution and 0.06 mcg/mL at 1:25 mcg/ mL serum dilution.
Calculation of sample size and statistical analysis. The study was designed to assess the ability of each regimen to elicit protective antibody responses in a predetermined proportion of participants, not for intergroup comparison. Acceptable regimens were defined as those for which Ͼ 90% of participants achieved antibody levels Ն 0.15 mcg/mL and Ͼ 70% of participants achieve levels Ն 1.0 mcg/mL. In order to have sufficient sample size to determine that 70% of the participants achieved protective levels, assuming an ␣ of 0.05 and power of 80%, we aimed to recruit 81 analyzable participants per group. To allow for loses to follow-up, we recruited 100 participants in each group-a total of 600 participants. Statistical analysis was done using SAS version 6.12 (SAS Institute, Cary, N.C.). Antibody concentrations were log transformed so that mean concentrations and confidence intervals could be calculated.
RESULTS
Between June 29 and August 5, 1998, we identified 665 age-eligible infants and enrolled 600. The parents of 65 infants refused consent to participate (Figure 1 ). Although the original randomization called for 100 in each group, there were three instances in which an infant was included in the wrong arm of the study. After the randomization was assigned, the study nurses made up the vaccine on site. In one instance, an infant assigned to regimen B was given the vaccine for regimen A; in another an infant assigned to regimen C was given the vaccine for regimen D; and in the final case, an infant was assigned to regimen B and given the vaccine for regimen E. Because the assignments were double-checked by two nurses and the study physician, the errors were detected at the time they occurred during the initial visit. After the first vaccination, folders were labeled with color-coded stickers to prevent errors in revaccination and each of these infants continued to receive the same vaccine dose that it had been given on the initial visit.
Of the 600 children whose parents consented to participation in the study, 507 returned on time for all of their visits. The most common reasons for loss to follow-up were parental refusal to continue and failure to return on time.
Comparison of demographic data between those who returned on time to all three visits and those who were lost to follow-up shows no significant differences. The number of analyzable sera at each interval was further reduced because the team was unable to draw a blood specimen from every child. This problem was greatest in the youngest infants. Thus, there were 486 analyzable sera following the first vaccine, 493 following the second, and 500 following the third. Table 1 presents a comparison of selected demographics and environmental factors among the 6 regimens. The groups were similar with respect to age, gender, return-rate, breast feeding, and socioeconomic status. Five hundred and seven children (84%) returned on time for all three followup visits. No cases of invasive Hib disease occurred in any of the study participants.
As seen in Table 2 , all six regimens met the predetermined definition of acceptable regimens with Ͼ 90% of participants achieving antibody levels Ն 0.15 mcg/mL and Ͼ 70% of participants achieving levels Ն 1.0 mcg/mL after 3 vaccinations. Table 3 shows that after 2 doses of vaccine, Ն 97% of participants in each group achieved antibody levels of Ն 0.15 mcg/mL and Ն 66% achieved levels greater than Ն 1.0 mcg/mL.
Among those who received Hib as a separate injection, geometric mean concentrations of antibodies (GMCs) at 1 month post Dose 3 were 11.2, 11.9, and 16.3 in the full, half, and one-third-dose groups, respectively. Among those who received Hib and DTP combined, the GMCs were 6.4, 5.2, and 5.7 in the full, half, and one-third-dose groups, respectively. Although there is an apparent trend towards increasing GMCs as the dose decreased among those who received Hib as a separate injection, this was not statistically significant and was not seen among those who received the vaccine combined with DTP.
DISCUSSION
Immunity to Hib disease is strongly correlated to levels of serum antibodies against the polysaccharide Hib capsule. * Vaccine regimen is the administration of PRP-T (polyribosylribitol phosphate-tetanus toxoid Hib vaccine) either separately (PRP-T and DTP separate) from DTP (diptheria, tetanus, and pertussis vaccine) or in combination with it (PRP-T and DTP combined). Hib ϭ Haemophilus influenzae type b. Cl ϭ confidence intervals.
While a precise antibody level required for protection has not been established, serum concentrations of anti-PRP antibody Ն 0.15 mcg/mL and Ն 1.0 mcg/mL, are widely regarded as surrogates for short-term and long-term protection, respectively. 22 This study demonstrates that fractional doses of PRP-T Hib elicit antibody levels greater than the accepted minimum protective levels in infants.
The data from this study are consistent with data from fractional dose and reduced antigen dose studies in Chile and elsewhere. 13 In Chile, Lagos and others administered fractional doses of Hib vaccine by reducing the volume of vaccine given from 0.5 mL (full dose) to 0.25 mL or 0.17 mL, thereby immunizing 2 or 3 infants from a single vial. In that study, 72-90% and 91-100% of infants who received the fractional dose regimens developed anti-PRP concentrations Ն 0.15 mcg/mL and Ն 1.0 mcg/mL, respectively, suggesting that current formulations of Hib vaccine contain more than enough antigen to stimulate protective antibody levels. Several manufacturers, in fact, are working to develop reduced-antigen Hib vaccines, and one manufacturer has already re-licensed their Hib conjugate vaccine with half the amount of antigen that was in the initially licensed formulation. 23 Re-licensure takes time and money, and thus it is unclear when these new preparations will be available and more importantly, whether any savings will accrue to the purchaser. This study and the Chilean study have shown that the immunologic basis exists for using fractional dose regimens, which may provide a substantial cost savings to the purchaser, not the manufacturer.
The demonstration of protective immunity following immunization with fractional dose regimens of Hib vaccine is not sufficient to assure that it will lead to a successful vaccination program against Hib. Introduction of any new vaccine will require some adjustments to the routine immunization schedule, and use of fractional dose regimens may require overcoming unique obstacles. For example, one issue to consider in planning a routine program of fractional dose vaccination is the volume of vaccine to be administered. This point is important because it will drastically affect issues of supply, administration, cold chain, storage, and training. Routine EPI vaccines are given in 0.5 mL volumes and as a result, the syringes in most clinics are not capable of reliably measuring smaller volumes. In Chile, the fractional doses of Hib vaccine were given as volumes (0.25 mL and 0.17 mL) smaller than the standard 0.5 mL dose, so required small tuberculin syringes for administration. The advantage of this approach is that no additional diluent is needed for the lyophilized formulation and that the it could be applied even to vaccines that come as a liquid formulation. In our study, unlike the study in Chile, we used a consistent volume of 0.5 mL for the administration of the fractional dose regimens. This approach was selected by the study team in order to demonstrate the significance of immunizing all children with 0.5 mL volume vaccines. Finally, we chose the PRP-T vaccine because it came in a lyophilized formula which allowed it to be reconstituted in such a way to administer a consistent volume which we felt would be programmatically more efficient. In practice, these regimens were easy to administer, and after one training session, all vaccinations went smoothly. However, this approach is an option for use with the lyophilized Hib conjugate vaccines only.
The use of vaccines in fractional dose regimens is not an approach that should be applied to all vaccines and may not be useful in all countries. The use of fractional dose regimens represents an off-label use of vaccine. In countries where a national control authority exists, its approval should be obtained before vaccine use in this manner. However, it may be an option to consider in countries where Hib disease is a serious public health problem that is not being addressed because of the cost of the vaccine, where the vaccination program is able to incorporate this approach, and where the political will exists to support efforts to prevent Hib disease immediately by introducing Hib vaccine in an off-label regimen.
While the results of this study strongly suggest that fractional doses of Hib vaccine provide adequate protection, this study may not be representative of all children or all vaccination centers in the Dominican Republic. Introduction of any new vaccine requires that local capacity exists to administer existing and new vaccines; that there is sufficient cold chain and storage capacity to incorporate the new vaccines; that vaccinators be trained in the handling and administration requirements of the new product; and that the im-pact on production or procurement of other vaccines be considered. As with the introduction of any vaccine, the introduction of a fractional dose regimen should be closely monitored to assess the clinical impact of the vaccine and any programmatic complications. The cost of such an approach in comparison to current methods should also be assessed.
More and more new vaccines will become available with time. Market competition will eventually bring the prices down, but as we have seen with Hib, this can take more than ten years. Alternative regimens may offer a way for countries with few resources to introduce vaccines sooner than would otherwise be possible. This study suggests that alternative regimens could offer acceptable levels of protection and allow the introduction of Hib vaccine in some countries that cannot currently afford it.
